JP2020518673A5 - - Google Patents

Download PDF

Info

Publication number
JP2020518673A5
JP2020518673A5 JP2020511868A JP2020511868A JP2020518673A5 JP 2020518673 A5 JP2020518673 A5 JP 2020518673A5 JP 2020511868 A JP2020511868 A JP 2020511868A JP 2020511868 A JP2020511868 A JP 2020511868A JP 2020518673 A5 JP2020518673 A5 JP 2020518673A5
Authority
JP
Japan
Prior art keywords
acid
cancer
compound according
compound
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020511868A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020518673A (ja
JP7693317B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/031228 external-priority patent/WO2018204869A1/en
Publication of JP2020518673A publication Critical patent/JP2020518673A/ja
Publication of JP2020518673A5 publication Critical patent/JP2020518673A5/ja
Priority to JP2023065085A priority Critical patent/JP2023090748A/ja
Application granted granted Critical
Publication of JP7693317B2 publication Critical patent/JP7693317B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020511868A 2017-05-05 2018-05-04 二官能性キレートの薬物動態増強及びその使用 Active JP7693317B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023065085A JP2023090748A (ja) 2017-05-05 2023-04-12 二官能性キレートの薬物動態増強及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762502260P 2017-05-05 2017-05-05
US62/502,260 2017-05-05
PCT/US2018/031228 WO2018204869A1 (en) 2017-05-05 2018-05-04 Pharmacokinetic enhancements of bifunctional chelates and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023065085A Division JP2023090748A (ja) 2017-05-05 2023-04-12 二官能性キレートの薬物動態増強及びその使用

Publications (3)

Publication Number Publication Date
JP2020518673A JP2020518673A (ja) 2020-06-25
JP2020518673A5 true JP2020518673A5 (enExample) 2021-04-22
JP7693317B2 JP7693317B2 (ja) 2025-06-17

Family

ID=64016761

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020511868A Active JP7693317B2 (ja) 2017-05-05 2018-05-04 二官能性キレートの薬物動態増強及びその使用
JP2023065085A Pending JP2023090748A (ja) 2017-05-05 2023-04-12 二官能性キレートの薬物動態増強及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023065085A Pending JP2023090748A (ja) 2017-05-05 2023-04-12 二官能性キレートの薬物動態増強及びその使用

Country Status (15)

Country Link
US (2) US11191854B2 (enExample)
EP (1) EP3619191A4 (enExample)
JP (2) JP7693317B2 (enExample)
KR (1) KR102612882B1 (enExample)
CN (2) CN111263747B (enExample)
AU (3) AU2018261888B2 (enExample)
BR (1) BR112019023246B1 (enExample)
CA (1) CA3062553C (enExample)
CL (1) CL2019003168A1 (enExample)
EA (1) EA201992595A1 (enExample)
IL (1) IL270453B2 (enExample)
MA (1) MA48861A (enExample)
RU (1) RU2019139432A (enExample)
WO (1) WO2018204869A1 (enExample)
ZA (1) ZA201908071B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10758636B2 (en) * 2013-11-12 2020-09-01 Centre For Probe Development And Commercialization Residualizing linkers and uses thereof
JP7191938B2 (ja) * 2017-05-05 2022-12-19 センター・フォー・プローブ・デベロップメント・アンド・コマーシャライゼイション Igf-1rモノクローナル抗体及びその使用
RU2019139432A (ru) 2017-05-05 2021-06-07 Сентр фор Проуб Девелопмент энд Коммерсиализэйшн Фармакокинетическая оптимизация бифункциональных хелатов и их применение
US20210236664A1 (en) * 2018-04-25 2021-08-05 The Johns Hopkins University Alpha particle formulations for treatment of solid tumors
AU2019287595B2 (en) * 2018-04-27 2024-10-31 University Of Iowa Research Foundation Compositions for chelating metals at low temperatures
MA54401A (fr) * 2018-12-03 2021-10-13 Fusion Pharmaceuticals Inc Polythérapie associant des radioimmunoconjugués et des inhibiteurs de réparation des dommages à l'adn
AU2019435951B2 (en) * 2019-03-20 2025-08-14 Provincial Health Services Authority Chelators and methods of making and using same
EP4087621A4 (en) * 2020-01-10 2024-01-17 Fusion Pharmaceuticals Inc. MACROCYCLIC CHELATES AND USES THEREOF
BR112022013681A2 (pt) * 2020-01-10 2022-11-16 Fusion Pharmaceuticals Inc Imunoterapia sustentada
WO2021195131A1 (en) * 2020-03-23 2021-09-30 Fusion Pharmaceuticals Inc. Fgfr3-targeted radioimmunoconjugates and uses thereof
KR102362962B1 (ko) * 2020-06-12 2022-02-16 (주)미래바이오팜 신규한 화합물 및 이를 함유하는 신경 손상, 신경 질환, 또는 발달 장애에 대한 신경세포의 증식 촉진, 분화, 및/또는 재생을 통한 치료 또는 예방용 약제학적 조성물
WO2022025184A1 (ja) * 2020-07-29 2022-02-03 中外製薬株式会社 非放射性物質で標識した薬剤の薬物動態を測定する方法
WO2022198319A1 (en) * 2021-03-23 2022-09-29 Fusion Pharmaceuticals Inc. Use of a cold fgfr3-targeting molecule and a fgfr3 targeting radioimmunoconjugate for treating cancer
WO2022266499A1 (en) * 2021-06-17 2022-12-22 Mayo Foundation For Medical Education And Research Methods and materials for combining biologics with multiple chelators
WO2023164777A1 (en) * 2022-03-04 2023-09-07 Fusion Pharmaceuticals Inc. Gucy2c-targeted radiopharmaceuticals and use thereof
WO2023240135A2 (en) 2022-06-07 2023-12-14 Actinium Pharmaceuticals, Inc. Bifunctional chelators and conjugates
EP4637843A2 (en) * 2022-12-21 2025-10-29 Mayo Foundation for Medical Education and Research Methods and materials for combining biologics with multiple chelators

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5175343A (en) 1985-01-14 1992-12-29 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
DE3713842A1 (de) * 1987-04-22 1988-11-17 Schering Ag Substituierte cyclische komplexbildner, komplexe und komplexsalze, verfahren zu deren herstellung und diese enthaltende pharmazeutische mittel
US4889931A (en) 1988-09-27 1989-12-26 Salutar, Inc. Manganese (II) chelate manufacture
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ATE133165T1 (de) 1989-02-10 1996-02-15 Celltech Therapeutics Ltd Aza-macrozyklen und verfahren zu deren herstellung
US5053503A (en) 1989-02-17 1991-10-01 Centocor Chelating agents
US5364613A (en) 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
US6274713B1 (en) 1989-04-07 2001-08-14 Salutar, Inc. Polychelants
US7385041B2 (en) 1990-04-25 2008-06-10 Bracco International B.V. Dual functioning excipient for metal chelate contrast agents
CA2044737A1 (en) 1990-06-18 1991-12-19 Jaime Simon Use of macrocyclic aminophosphonic acid complexes as imaging agents
US5386011A (en) 1990-12-27 1995-01-31 Abbott Laboratories Hexapeptide anaphylatoxin-receptor ligands
GB9112536D0 (en) * 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
AU2238292A (en) 1991-06-14 1993-01-12 Xoma Corporation Microbially-produced antibody fragments and their conjugates
CA2134239C (en) 1992-06-09 2004-11-23 Donald B. Axworthy Pretargeting methods and compounds
US5358704A (en) 1993-09-30 1994-10-25 Bristol-Myers Squibb Hepatobiliary tetraazamacrocyclic magnetic resonance contrast agents
GB9504922D0 (en) 1995-03-10 1995-04-26 Nycomed As Process
SI0970126T1 (en) 1997-04-14 2001-08-31 Micromet Ag Novel method for the production of antihuman antigen receptors and uses thereof
IT1291624B1 (it) 1997-04-18 1999-01-11 Bracco Spa Chelati complessi di metalli paramagnetici a bassa tossicita'
IT1304501B1 (it) 1998-12-23 2001-03-19 Bracco Spa Uso di derivati di acidi biliari coniugati con complessi metallicicome "blood pool agents" per l'indagine diagnostica tramite risonanza
CA2371728C (en) 1999-06-11 2009-06-02 Neorx Corporation High dose radionuclide complexes for bone marrow suppression
DE10002939C1 (de) 2000-01-13 2001-09-20 Schering Ag Paramagnetische DOTA-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung für die Herstellung von pharmazeutischen Mitteln
US20020052354A1 (en) 2000-01-27 2002-05-02 Schering Ag Paramagnetic DOTA derivatives, pharmaceutical agents that contain the latter, process for their production, and their use for MR imaging of necrosis and infarction
US6264966B1 (en) 2000-02-22 2001-07-24 Concat, Ltd. Compounds with chelation affinity and selectivity for first transition elements and their use in cosmetics and personal care products, inhibition of metalloenzymes, and inhibition of reperfusion injury
JP2004509152A (ja) 2000-05-12 2004-03-25 ユニバーシティ ホスピタル 放射性金属標識分子のプロキレート剤
JP2004536034A (ja) 2001-01-08 2004-12-02 ネオルクス コーポレイション 治療的および診断的化合物、組成物および方法
DE10135355C1 (de) 2001-07-20 2003-04-17 Schering Ag Konjugate makrocyclischer Metallkomplexe mit Biomolekülen und deren Verwendung zur Herstellung von Mitteln für die NMR- und Radiodiagnostik sowie die Radiotherapie
DE10135356C1 (de) 2001-07-20 2003-04-17 Schering Ag Makrocyclische Metallkomplexe und deren Verwendung zur Herstellung von Konjugaten mit Biomolekülen
TWI240632B (en) 2001-07-30 2005-10-01 Epix Medical Inc Purified peptides for peptide-based multimeric targeted contrast agents
EP1542709A2 (en) 2002-08-06 2005-06-22 EPIX Pharmaceuticals, Inc. Peptide aggregates
DE10250870A1 (de) 2002-10-31 2004-05-13 Switch Biotech Ag Zusammensetzung enthaltend Aktivatoren von IK-Kaliumkanälen und Calcineurin-Antagonisten und deren Verwendung
JP2006517558A (ja) 2003-02-13 2006-07-27 ブラッコ イメージング エッセ ピ ア コントラスト増強x線位相画像診断
EP1603598B1 (en) * 2003-03-19 2008-10-08 Universitätsspital Basel Radiolabeled conjugates based on substance p and the uses thereof
CA2526760A1 (en) 2003-05-23 2005-01-06 Epix Pharmaceuticals, Inc. Optically pure and enriched isomers of chelating ligands and contrast agents
JP4262545B2 (ja) 2003-07-09 2009-05-13 三菱電機株式会社 カスコード接続回路及びその集積回路
JP2007505315A (ja) 2003-09-12 2007-03-08 インヴィトロジェン コーポレーション 多重結合および活性アッセイ
AU2004303425C1 (en) 2003-12-19 2010-02-18 Schering Corporation Pharmaceutical compositions
WO2005079803A1 (en) 2004-02-13 2005-09-01 Pfizer Products, Inc. Compounds for treatment of cardiovascular diseases
WO2006015318A2 (en) 2004-07-30 2006-02-09 Biogen Idec Inc. Antibody conjugated to a drug moiety via a poptidic linker
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
US20060222595A1 (en) 2005-03-31 2006-10-05 Priyabrata Mukherjee Nanoparticles for therapeutic and diagnostic applications
US7618957B2 (en) 2005-07-15 2009-11-17 Bayer Schering Pharma Aktiengesellschaft Perfluoroalkyl-containing complexes, process for their production as well as their use
EP1904462A2 (de) 2005-07-15 2008-04-02 Bayer Schering Pharma Aktiengesellschaft Perfluoralkylhaltige komplexe, verfahren zu deren herstellung, sowie deren verwendung
US20100226884A1 (en) * 2009-01-20 2010-09-09 Immunomedics, Inc. Novel Class of Monospecific and Bispecific Humanized Antibodies that Target the Insulin-like Growth Factor Type I Receptor (IGF-1R)
US8034898B2 (en) 2005-12-29 2011-10-11 Collagen Medical, LLC Methods of collagen imaging
EP2065057A3 (en) 2006-03-15 2009-08-12 Mallinckrodt Inc. Chelating conjugates having a substituted aromatic moiety and derivatives thereof
US7777029B2 (en) 2006-05-02 2010-08-17 San Diego State University (Sdsu) Foundation Bifunctional chelators for sequestering lanthanides
US20080213811A1 (en) 2006-08-11 2008-09-04 Invitrogen Corporation Sensor proteins and assay methods
US8691761B2 (en) * 2006-10-16 2014-04-08 Jean E. F. Rivier Somatostatin receptor 2 antagonists
GB0624587D0 (en) 2006-12-08 2007-01-17 Univ Muenchen Tech Chelating agent
US20100111858A1 (en) * 2007-01-19 2010-05-06 Howard Carol P Diangostic and Therapeutic Cyclooxygenase-2 Binding Ligands
WO2008134289A2 (en) 2007-04-26 2008-11-06 Mallinckrodt Inc. High relaxivity coordinatively unsaturated lanthanide complexes
ES2676598T3 (es) 2007-08-27 2018-07-23 Liebel-Flarsheim Company Llc Eliminación de sílice a partir de compuestos hidrosolubles mediante nanofiltración y cromatografía en fase inversa
CA2697612A1 (en) 2007-08-28 2009-03-12 Biogen Idec Ma Inc. Anti-igf-1r antibodies and uses thereof
US20090208421A1 (en) 2008-02-19 2009-08-20 Dominique Meyer Process for preparing a pharmaceutical formulation of contrast agents
DE102008045937B4 (de) 2008-04-11 2017-01-26 Johannes-Gutenberg-Universität Mainz Radiopharmakon aus einem Metallion und einem Markierungsvorläufer und Verwendung des Radiopharmakons
US8546531B2 (en) 2008-07-16 2013-10-01 The General Hospital Corporation Methods and reagents for preparing multifunctional probes
EP2147684A1 (en) 2008-07-22 2010-01-27 Bracco Imaging S.p.A Diagnostic Agents Selective Against Metalloproteases
CN102271713B (zh) 2008-11-06 2013-07-31 路易莎·布拉奇 神经降压肽衍生的分枝肽及其用途
WO2010088527A2 (en) 2009-01-30 2010-08-05 Mayo Foundation For Medical Education And Research Peptides and nanoparticles for therapeutic and diagnostic applications
MX2011009716A (es) 2009-03-19 2011-10-17 Wyeth Llc Metodos para la preparacion de acido [2-(8,9-dioxo)-2,6-diazabicic lo[5.2.0]non-1(7)-en-2-il)etil]fosfonico y precursores de este.
WO2011005609A2 (en) 2009-07-08 2011-01-13 Mayo Foundation For Medical Education And Research Imaging gastrointestinal volumes and motility
EP2515914A4 (en) 2009-12-23 2013-09-11 Scripps Research Inst BIOCONJUGATION OF TYROSINE BY EYE REACTIONS IN AQUEOUS MEDIA
EP3075390A1 (en) 2010-01-19 2016-10-05 Immunomedics Inc. Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r)
EP2397466B1 (en) 2010-06-15 2012-11-28 Centre National De La Recherche Scientifique CNRS X-ray and gamma-photon activatable organic compounds, their preparation and their uses
US9573978B2 (en) 2010-08-12 2017-02-21 S&T Global, Inc. Cyclosporin derivatives for the treatment and prevention of a viral infection
US12097269B2 (en) 2010-10-27 2024-09-24 Vikas Kundra Dual mode gadolinium nanoparticle contrast agents
FR2968999B1 (fr) 2010-12-20 2013-01-04 Guerbet Sa Nanoemulsion de chelate pour irm
US20140088019A1 (en) 2011-02-11 2014-03-27 Zyngenia, Inc. Monovalent and Multivalent Multispecific Complexes and Uses Thereof
WO2012122420A2 (en) 2011-03-09 2012-09-13 Pharmacofore, Inc. Opioid prodrugs with heterocyclic linkers
PL2721045T3 (pl) 2011-06-20 2017-11-30 Radiomedix Inc. Kompozycie, metody syntezy i zastosowanie węglowodanowych środków ukierunkowanych
FR2976825B1 (fr) 2011-06-22 2014-02-21 Total Sa Nanotraceurs pour le marquage d'eaux d'injection de champs petroliers
EP2604281B1 (en) 2011-12-14 2014-07-30 Centre National de la Recherche Scientifique (CNRS) Clicked somatostatin conjugated analogs for biological applications
KR20130083592A (ko) 2012-01-13 2013-07-23 현대약품 주식회사 치환된 피페리딘 유도체 및 이의 제조방법
EP2852685A1 (en) 2012-03-30 2015-04-01 Merck Sharp & Dohme Corp. Igf1 biomarker for igf1r inhibitor therapy
KR20150030709A (ko) 2012-06-14 2015-03-20 얀센 바이오테크 인코포레이티드 인간 배아 줄기 세포의 췌장 내분비 세포로의 분화
CN102743770B (zh) 2012-06-18 2017-07-21 申宝忠 一种靶向性分子成像探针及活体分子成像方法
EP2892570B1 (en) 2012-09-07 2019-02-27 Bracco Imaging S.p.A Paramagnetic solid lipid nanoparticles (pslns) containing metal amphiphilic complexes for mri
US9931412B2 (en) 2013-02-08 2018-04-03 The Regents Of The University Of Michigan Targeted theranostics
CA2911259A1 (en) 2013-05-06 2014-11-13 Merck Patent Gmbh Macrocycles as kinase inhibitors
WO2015023979A1 (en) 2013-08-16 2015-02-19 Equip, Llc Discrete peg constructs
US10471163B2 (en) 2013-09-13 2019-11-12 The General Hospital Corporation Activatable fibrin-binding probes
AU2014336638C1 (en) 2013-10-18 2020-09-17 Novartis Ag Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
US10758636B2 (en) * 2013-11-12 2020-09-01 Centre For Probe Development And Commercialization Residualizing linkers and uses thereof
WO2015085005A1 (en) 2013-12-03 2015-06-11 The General Hospital Corporation Molecular imaging probes
FR3015547B1 (fr) 2013-12-20 2016-01-01 Total Sa Methode pour ajuster le taux d'inhibiteurs dans un puits de petrole ou de gaz
GB201403875D0 (en) 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
CN106459205B (zh) 2014-04-11 2021-04-09 免疫医疗有限责任公司 包含半胱氨酸工程化抗体的轭合化合物
HUE049622T2 (hu) 2014-04-25 2020-09-28 Rinat Neuroscience Corp Magas drog-töltöttségû ellenanyag-drog konjugátumok
CA2949365A1 (en) * 2014-05-16 2015-11-19 Memorial Sloan Kettering Cancer Center One-step labeling of antibodies to high specific activity with actinium-225
WO2016016329A1 (en) 2014-07-29 2016-02-04 Vrije Universiteit Brussel Radio-labelled antibody fragments for use in the prognosis, diagnosis of cancer as well as for the prediction of cancer therapy response
BE1021191B1 (fr) 2014-08-29 2015-10-27 Anmi S.A. Kit pour radiomarquage.
GB201417067D0 (en) 2014-09-26 2014-11-12 South African Nuclear Energy Radiopharmaceutical conjugate
DE102014115154A1 (de) 2014-10-17 2016-04-21 SCV-SpezialChemikalien-Vertrieb GmbH Konjugierte Bisphosphonate für die Diagnostik und Therapie von Knochenerkrankungen
ES2822990T3 (es) 2014-11-25 2021-05-05 Bristol Myers Squibb Co Novedosos polipéptidos de unión a PD-L1 para obtención de imágenes
US20190015518A1 (en) * 2016-01-04 2019-01-17 University Of Kansas Drug delivery compositions and methods
US10758634B2 (en) 2016-03-18 2020-09-01 Wake Forest University Compounds, compositions and associated methods using zirconium-89 in immuno-positron emission tomography
CN108924931B (zh) * 2017-03-24 2024-05-07 中兴通讯股份有限公司 一种无线资源配置方法、装置及用户设备、网络节点
JP7191938B2 (ja) 2017-05-05 2022-12-19 センター・フォー・プローブ・デベロップメント・アンド・コマーシャライゼイション Igf-1rモノクローナル抗体及びその使用
US10093741B1 (en) * 2017-05-05 2018-10-09 Fusion Pharmaceuticals Inc. IGF-1R monoclonal antibodies and uses thereof
RU2019139432A (ru) 2017-05-05 2021-06-07 Сентр фор Проуб Девелопмент энд Коммерсиализэйшн Фармакокинетическая оптимизация бифункциональных хелатов и их применение

Similar Documents

Publication Publication Date Title
JP2020518673A5 (enExample)
RU2019139432A (ru) Фармакокинетическая оптимизация бифункциональных хелатов и их применение
JP2020518674A5 (enExample)
JP2023090748A5 (enExample)
JP7304588B2 (ja) Psmaを標的としたイメージング及び放射線治療のための金属/放射性金属標識psma阻害剤
RU2019139434A (ru) Моноклональные антитела против igf-1r и их применение
Price et al. Matching chelators to radiometals for radiopharmaceuticals
JP2833766B2 (ja) アミノポリカルボン酸およびその誘導体
AU2018207190B2 (en) Treatment of cancer cells overexpressing somatostatin receptors using ocreotide derivatives chelated to radioisotopes
JP2024522200A (ja) トリスリンカー結合二量体化標識前駆体およびそれに由来する放射性トレーサー
CA3071315A1 (en) Dual mode radiotracer and -therapeutics
CN117563022A (zh) 可用于成像和抗肿瘤治疗的具有可调的药代动力学的三功能构建体
CN102438656A (zh) 预靶向试剂盒、方法和其中使用的试剂
CN108290924A (zh) 肽硫脲衍生物、含有其的放射性同位素标记化合物、和含有该化合物作为活性成分的用于治疗或诊断前列腺癌的药物组合物
KR20240158290A (ko) 핵의학에서 사용되는 테라노스틱스를 위한 3개 이상의 표적화 벡터를 갖는 전구체 표지자 및 방사성 추적자
JP2012533523A5 (enExample)
EP4423137A1 (en) Claudin 18.2-targeted compounds and uses thereof
KR20240099208A (ko) EGFRvIII-표적화 화합물 및 그의 용도
JP4878119B2 (ja) エナンチオマー純粋な(4S,8S)−及び(4R,8R)−4−p−ニトロベンジル−8−メチル−3,6,9−トリアザ−3N,6N,9N−トリカルボキシメチル−1,11−ウンデカン二酸及びそれらの誘導体、それらの製造方法並びに医薬品の製造のためのそれらの使用
US20240350682A1 (en) Steap2-targeted compounds and use thereof
WO2011102626A2 (ko) 폴리아자마크로사이클릭 화합물, 그 제조 방법 및 생의학적 적용
WO2024216389A9 (en) Claudin 18.2-targeted compounds and uses thereof
RU2025124374A (ru) Способы лечения глиобластомы
JP5162081B2 (ja) エナンチオマー純粋な(4S,8S)−及び(4R,8R)−4−p−ベンジル−8−メチル−3,6,9−トリアザ−3N,6N,9N−トリカルボキシメチル−1,11−ウンデカン二酸と生体分子との結合体、その塩の製造方法並びに医薬品の製造のためのそれらの使用
KR20250049308A (ko) 방사성 의약품용 규소계 불화물 수용기